drugset / Trial / NCT00673127
Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer
Phase 2
Completed
57 enrolled
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute · collabM.D. Anderson Cancer Center · collabMassachusetts General Hospital · collabOregon Health and Science University · collabSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · collabSunnybrook Health Sciences Centre · collab
NaSingle-groupOpen-labelTreatment
Summary
The combination of ketaconazole and hydrocortisone is commonly used for the treatment of prostate cancer. The purpose of this study is to determine if the addition of a drug called dutasteride to this approved combination will make the combination more effective in treating prostate cancer.
Timeline
- Start
- 2005-02
- Primary completion
- 2012-02
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dutasteride | Small molecule | 0.5 mg | Oral |
| Background | Hydrocortisone | Other / unclassified | 10 mg | Oral |
| Background | Hydrocortisone | Other / unclassified | 30 mg | Oral |
| Background | Ketoconazole | Small molecule | 200 mg | — |